Resmed

ResMed Australia sells cloud-connected CPAP machines, masks, humidifiers and accessories for sleep apnoea therapy, plus portable oxygen concentrators and digital health software. Hardware sits in the premium price band—CPAP units AUD $1,200–$3,000, masks $200–$350—while consumables and parts are mid-range. Products are supplied through sleep clinics, hospital contracts and the company’s own e-commerce site, with prescription verification for devices. The brand’s core edge is embedded 4G/Bluetooth connectivity that streams nightly therapy data to clinicians and the myAir patient app, enabling remote titration and adherence coaching. Its AirSense 11 and AirMini platforms are the smallest connected CPAPs on the local market, and the company’s SaaS ecosystem (AirView, U-Sleep) is used by more than 15 million patients worldwide. Primary buyers are adults diagnosed with obstructive sleep apnoea—often middle-aged, health-insured and technology-comfortable—who value evidence-based outcomes and want to avoid in-lab follow-ups. Prescribers (sleep physicians, respiratory physiologists) choose ResMed to improve compliance metrics and reduce recall visits, aligning with Australia’s Medicare-funded remote-care incentives. Competitors include multinational med-tech firms offering lower-cost blower units and basic data cards; ResMed counters with end-to-end connectivity, clinical-grade algorithms and local service infrastructure. By bundling hardware, consumables and reimbursed digital coaching, the brand locks in recurring revenue and positions itself as a therapy partner rather than a commodity device vendor.